Avantor, Inc. Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Emmanuel Ligner; PEO total compensation $5.90M; PEO compensation actually paid $6.10M; Other NEO average total compensation $5.38M.
- 2024-12-31: PEO Michael Stubblefield; Other NEO average total compensation $3.43M.
- 2023-12-31: PEO Michael Stubblefield; Other NEO average total compensation $3.68M.
- 2022-12-31: PEO Michael Stubblefield; Other NEO average total compensation $2.55M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Emmanuel Ligner | $5.90M | $6.10M | $5.38M | $2.06M | $40.71 | $148.36 | -$530.20M | $6.55B | 2026-03-27 |
| 2024-12-31 | Michael Stubblefield | $3.43M | $1.78M | $116.09 | $146.87 | $711.50M | $6.78B | 2026-03-27 | ||
| 2023-12-31 | Michael Stubblefield | $3.68M | $2.49M | $125.79 | $143.18 | $321.10M | $6.97B | 2026-03-27 | ||
| 2022-12-31 | Michael Stubblefield | $2.55M | -$7.18M | $116.20 | $140.29 | $686.50M | $7.51B | 2026-03-27 | ||
| 2021-12-31 | Michael Stubblefield | $3.54M | $12.02M | $232.18 | $143.09 | $572.60M | $7.39B | 2026-03-27 | ||
| 2024-12-31 | Michael Stubblefield | $14.53M | $11.18M | $3.43M | $1.78M | $116.09 | $146.87 | $711.50M | $6.78B | 2025-03-28 |
| 2023-12-31 | $12.34M | $8.93M | $3.68M | $2.49M | $125.79 | $143.18 | $321.10M | $6.97B | 2025-03-28 | |
| 2022-12-31 | $10.83M | -$28.63M | $2.55M | -$7.18M | $116.20 | $140.29 | $686.50M | $7.51B | 2025-03-28 | |
| 2021-12-31 | $13.26M | $45.71M | $3.54M | $12.02M | $232.18 | $143.09 | $572.60M | $7.39B | 2025-03-28 | |
| 2020-12-31 | $11.26M | $34.00M | $4.59M | $10.68M | $155.10 | $113.45 | $116.60M | $6.39B | 2025-03-28 | |
| 2023-12-31 | Michael Stubblefield | $12.34M | $8.93M | $3.68M | $2.49M | $125.79 | $143.18 | $321.10M | Adjusted EBITDA $1.31B | 2024-03-29 |
| 2022-12-31 | $10.83M | -$28.63M | $2.55M | -$7.18M | $116.20 | $140.29 | $686.50M | $1.57B | 2024-03-29 | |
| 2021-12-31 | $13.26M | $45.71M | $3.54M | $12.02M | $232.18 | $143.09 | $572.60M | $1.46B | 2024-03-29 | |
| 2020-12-31 | $11.26M | $34.00M | $4.59M | $10.68M | $155.10 | $113.45 | $116.60M | $1.14B | 2024-03-29 | |
| 2022-12-31 | Michael Stubblefield | $10.83M | -$28.63M | $2.55M | -$7.18M | $116.20 | $140.29 | $686.50M | Adjusted EBITDA $1.57B | 2023-03-31 |
| 2021-12-31 | $13.26M | $45.71M | $3.54M | $12.02M | $232.18 | $143.09 | $572.60M | $1.46B | 2023-03-31 | |
| 2020-12-31 | $11.26M | $34.00M | $4.59M | $10.68M | $155.10 | $113.45 | $116.60M | $1.14B | 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |